A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.
Amr El ZawilyFrederick S VizeacoumarRenuka DahiyaSara L BanerjeeKalpana K BhanumathyHussain ElhasasnaGlinton HanoverJessica C SharpeMalkon G SanchezPaul GreidanusR Greg StaceyKyung-Mee MoonIlya AlexandrovJuha P HimanenDimitar B NikolovHumphrey FongeAaron P WhiteLeonard J FosterBingcheng WangBehzad M ToosiNicolas BissonTajib A MirzabekovFranco J VizeacoumarAndrew FreywaldPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our work not only presents a new bispecific antibody with a high potential for being developed into clinically relevant biologics, but more importantly, successfully validates a novel unbiased strategy for selecting biologically optimal target combinations. This is of a significant translational relevance, as such multifaceted unbiased approaches are likely to augment the development of effective combination therapies for cancer treatment.